NASDAQ$PRPO
Precipio Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Precipio achieved positive Adjusted EBITDA and positive cash flow in Q4 2024, demonstrating progress towards financial independence.
Precipio, Inc. reported positive Adjusted EBITDA of $0.4 million and a positive cash flow increase of $0.3 million in Q4 2024, indicating a significant step towards financial independence and profitability.
- Achieved positive Adjusted EBITDA of $0.4 million for Q4 2024.
- Reported a positive cash flow increase of $0.3 million in Q4 2024.
- Demonstrated the ability to generate sufficient positive cash flow from pathology services to fund R&D and product business growth.
- Management believes the company is on track to become profitable, despite potential Q1 fluctuations due to insurance deductibles.
Headline financials
Revenue & EPS history
Precipio · Revenue · Quarterly
$5.45M
Revenue by segment
Precipio · $6.96M total across 2 segments · Q1 2026
- Service revenue$6.3M—90.5%
- Product revenue$659K—9.5%
Forward guidance
Precipio anticipates continued progress towards profitability and financial independence, leveraging current cash reserves and growth pipeline, despite potential short-term fluctuations.
Tailwinds
- Company is on track to turn the corner and become a profitable company.
- Ability to make decisions based on growth and value creation without cash conservation constraints.
- Focus on building capabilities and channeling resources towards product development and business growth.
- Current cash reserves and growth pipeline support future endeavors.
- Anticipates an exciting year ahead for the company.
Headwinds
- Financial performance in future quarters may fluctuate from positive to negative due to various factors.
- Pathology business revenues and cash receipts are typically reduced in Q1 due to renewed insurance deductibles.
- Operating results in Q1 may be affected by insurance deductibles, though less so in Q2.
- The company may still face ups and downs as the business grows.
- Forward-looking statements are subject to known and unknown risks and uncertainties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
-2.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-10.0%
Avg return
30 days after
49%
17 / 35 earnings
Positive
+13.3%
Q1 2021
Best reaction
-55.0%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | -14.0% | — | |
| Q3 2025 | +0.0% | +32.5% | +24.5% | |
| Q2 2025 | +2.9% | +0.1% | +36.5% | |
| Q1 2025 | +3.1% | +29.5% | +56.5% | |
| Q4 2024 | -9.9% | -15.9% | +1.3% | |
| Q3 2024 | +1.9% | -3.2% | -6.7% | |
| Q2 2024 | +0.8% | +3.4% | +22.5% | |
| Q1 2024 | -0.6% | +0.2% | -7.8% | |
| Q4 2023 | +2.1% | -5.7% | -10.1% | |
| Q3 2023 | -5.0% | -13.2% | -27.1% | |
| Q2 2023 | -3.5% | +0.8% | -8.4% | |
| Q1 2023 | -1.7% | +0.7% | -21.5% | |
| Q4 2022 | +3.7% | +6.9% | -4.7% | |
| Q3 2022 | +8.6% | +5.7% | -11.2% | |
| Q2 2022 | +2.6% | -11.8% | -33.6% | |
| Q1 2022 | -10.5% | -7.0% | +2.6% | |
| Q4 2021 | +0.0% | +24.4% | -20.7% | |
| Q3 2021 | -10.8% | -15.5% | -21.6% | |
| Q2 2021 | -2.9% | -9.8% | -1.0% | |
| Q1 2021 | +13.3% | +19.6% | +10.7% | |
| Q4 2020 | +3.9% | +1.3% | -95.8% | |
| Q3 2020 | +2.8% | -0.9% | +6.0% | |
| Q2 2020 | +3.3% | -16.3% | -31.3% | |
| Q1 2020 | +0.1% | +6.1% | +45.7% | |
| Q4 2019 | -9.6% | -12.9% | -24.4% | |
| Q3 2019 | -5.1% | -8.9% | -22.6% | |
| Q2 2019 | +5.8% | -5.4% | -8.8% | |
| Q1 2019 | -10.4% | -14.9% | -42.8% | |
| Q4 2018 | +3.2% | +19.6% | +12.3% | |
| Q3 2018 | +2.1% | -5.0% | -39.7% | |
| Q2 2018 | -2.0% | +1.9% | -10.9% | |
| Q1 2018 | +8.1% | +19.2% | -4.9% | |
| Q4 2017 | -8.2% | -7.1% | -22.4% | |
| Q3 2017 | -9.5% | -5.8% | -16.1% | |
| Q2 2017 | -55.0% | -55.2% | -65.2% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro